2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1368

One Size Fits All : Replacing ESR by γGT in DAS28 Calculation Permits a Dual Evaluation of Joint Activity Together with Cardiovascular Risk
Abstract Number: 1100

Opioid Overdose Hospitalizations in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 2048

Opioid Prescription Use Among Patients with Rheumatic Disease: A Population Based Cohort Study
Abstract Number: 215

Opioid Treatment Pattern in a Community Based Rheumatology Clinic
Abstract Number: 2480

Opioid Use Surrounding Diagnosis of Inflammatory Arthritis
Abstract Number: 2056

Opioids Use Among Medicare Beneficiaries with Knee Osteoarthritis: Prevalence and Correlates of Chronic Use
Abstract Number: 2291

Optimal Hydroxychloroquine Drug Levels in Pregnant Women with Systemic Lupus Erythematosus
Abstract Number: 2801

Optimal Threshold of Walking Speed Predictive of Mortality Risk over 9 Years in Knee Osteoarthritis: Data from Osteoarthritis Initiative
Abstract Number: 2680

Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients
Abstract Number: 1135

Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial
Abstract Number: 1001

Oral Collagen Type V Supplementation Inhibits Cartilage Degeneration in Experimental Arthritis
Abstract Number: 1740

Orange Brown Chromonychia in Kawasaki Disease: A Clinical Sign That Merits Greater Attention
Abstract Number: 1609

Organ Damage Free Survival in Southern Chinese Patients with Active Lupus Nephritis
Abstract Number: 1310

Osteoarthritis: What’s in a Name?
Abstract Number: 272

Osteoporosis Management Outcomes in a Southern California County Health System

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].